870837-70-0

Basic information

• Product Name: Benzaldehyde, 4-(1H-imidazol-1-yl)-3-methoxy-
• Synonyms: Benzaldehyde, 4-(1H-imidazol-1-yl)-3-methoxy-;4-(1H-iMidazol-1-yl)-3-Methoxybenzaldehyde;4-imidazol-1-yl-3-methoxybenzaldehyde
• CAS NO: 870837-70-0
• Molecular Formula: C₁₁H₁₀N₂O₂
• Molecular Weight: 202.2093
• Mol File: 870837-70-0.mol

Chemical Properties

• Boiling Point: 403.2°C at 760 mmHg
• Flash Point: 197.7°C
• Appearance: /
• Density: 1.18g/cm³
• Vapor Pressure: 1.03E-06mmHg at 25°C
• Refractive Index: 1.583
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Benzaldehyde, 4-(1H-imidazol-1-yl)-3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 4-(1H-imidazol-1-yl)-3-methoxy-(870837-70-0)
• EPA Substance Registry System: Benzaldehyde, 4-(1H-imidazol-1-yl)-3-methoxy-(870837-70-0)

Safety Data

• Hazardous Substances Data: 870837-70-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Benzaldehyde, 4-(1H-imidazol-1-yl)-3-methoxyis used as a pharmaceutical intermediate for the development of new drugs. Its unique structure, which includes a 1H-imidazol-1-yl group and a methoxy group, may contribute to the compound's biological activity and pharmacological properties, making it a promising candidate for the creation of novel therapeutic agents.

InChI:InChI=1/C11H10N2O2/c1-15-11-6-9(7-14)2-3-10(11)13-5-4-12-8-13/h2-8H,1H3

Upstream product

• 288-32-4 1H-imidazole 
• 870837-18-6 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde 
• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 1269834-33-4 C₁₁H₁₂N₂O₂ 
• 1269834-29-8 methyl 4-(1H-imidazol-1-yl)-3-methoxybenzoate 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 700834-18-0 4-formylamino-3-methoxybenzoic acid methyl ester 
• 870837-21-1 3-methoxy-4-(4-methylimidazol-1-yl)benzoic acid methyl ester 
• 870837-20-0 4-[formyl-(2-oxopropyl)amino]-3-methoxybenzoic acid methyl ester 
• 619-14-7 3-hydroxy-4-nitro-benzoic acid 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 

Downstream Products

• 870837-69-7 4-(5-chloro-1H-imidazol-1-yl)-3-methoxybenzaldehyde 
• 870837-68-6 4-(2-chloro-1H-imidazol-1-yl)-3-methoxybenzaldehyde 
• 958245-14-2 4-(1H-imidazol-1-yl)-3-methoxybenzoic acid 
• 1093980-61-0 1-(4-ethynyl-2-methoxyphenyl)-1H-imidazole 

Relevant articles and documents

Cation Radical Accelerated Nucleophilic Aromatic Substitution via Organic Photoredox Catalysis

Nucleophilic aromatic substitution (SNAr) is a direct method for arene functionalization; however, it can be hampered by low reactivity of arene substrates and their availability. Herein we describe a cation radical-accelerated nucleophilic aromatic substitution using methoxy- and benzyloxy-groups as nucleofuges. In particular, lignin-derived aromatics containing guaiacol and veratrole motifs were competent substrates for functionalization. We also demonstrate an example of site-selective substitutive oxygenation with trifluoroethanol to afford the desired trifluoromethylaryl ether.

Synthesis and preliminary evaluation of curcumin analogues as cytotoxic agents

A series of curcumin analogues with different substituents at the 4-position of the phenyl group were synthesized and screened for in vitro cytotoxicity against a panel of human cancer cell lines. Several novel curcumin analogues, especially 32 and 34, exhibited selective and potent cytotoxic activity against human epidermoid carcinoma cell line A-431 and human glioblastoma cell line U-251, implying their specific potential in the chemoprevention and chemotherapy of skin cancer and glioma. The preliminary SAR information extracted from the results suggested that introduction of appropriate substituents to the 4′-positions could be a promising approach for the development of new cytotoxic curcumin analogues with special selectivity for A-431 and U-251 cell lines.

UREA TYPE CINNAMIDE DERIVATIVE

Disclosed is a compound represented by the formula (I) below or a pharmacologically acceptable salt thereof. Also disclosed is a use of the compound or salt as a pharmaceutical product. (In the formula, Ar1 represents an imidazolyl group which may be substituted with a C1-6 alkyl group; Ar2 represents a phenyl group which may be substituted with a C1-6 alkoxy group; X1 represents a single bond; R1 and R2 respectively represent a C1-6 alkyl group or the like which may be substituted with a substituent such as a 5- to 14-membered aromatic heterocyclic group; and R3 represents a hydrogen atom or the like.)

TRIAZOLE DERIVATIVES FOR TREATING ALZHEIMER'S DISEASE AND RELATED CONDITIONS

Compounds of formula I: Selectively attenuate production of Aβ(1-42) and hence find use in treatment or prevention of diseases associated with deposition of Aβ in the brain, in particular Alzheimer's disease.

Cinnamide compound

The present invention relates to a compound represented by Formula (I): (wherein Ar1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R1 and R2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents. The object of the present invention is to find a therapeutic or preventive agent for diseases caused by Aβ. According to the present invention, a therapeutic or preventive agents for diseases caused by Aβ can be provided.